首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Journal of psoriasis and psoriatic arthritis

缩写:

ISSN:2475-5303

e-ISSN:2475-5311

IF/分区:0.0/

文章目录 更多期刊信息

共收录本刊相关文章索引99
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Mildred Min,Ajay S Dulai,Nabeel Ahmad et al. Mildred Min et al.
Background: Psoriasis is a chronic inflammatory condition with cutaneous and systemic involvement. Although many efficacious treatment options are available, concerns regarding costs and duration of treatment have expande...
Divya M Shan,Jonathan D Greenzaid,Estay Greene et al. Divya M Shan et al.
Pharmaceutical expenditures in the United States, particularly in dermatology, have grown rapidly, driven by expensive topical and biologic treatments. Insurers are employing cost-containing strategies such as step therapy, which mandates t...
Yvonne Nong,Dana M Walsh,Jessica Maloh et al. Yvonne Nong et al.
Background: Psoriasis is an immune-mediated cutaneous disease that may have shifts in the skin microbiome. Prior research on the skin microbiome in psoriasis has been limited to rRNA based approaches that lack resolution ...
Christopher Willy Schwarz,Lone Skov,Alexander Egeberg et al. Christopher Willy Schwarz et al.
Background: Psoriasis is associated with several comorbidities and patients with psoriasis are more often obese than individuals without psoriasis. The excess disease burden is important to consider in choice of and respo...
Nasim Niknezhad,Mohammad Shahidi-Dadras,Fateme Rajabi et al. Nasim Niknezhad et al.
Background: Numerous studies have documented an association between psoriasis and subclinical atherosclerosis. Objective: We aimed to i...
Christine Learned,Sara Alsukait,Kristin R Fiumara et al. Christine Learned et al.
Background: Specialty medications provide effective treatment with limited adverse effects to patients with psoriasis and psoriatic arthritis; however, variable coverage and high costs often create a barrier to treatment ...
Edward Hadeler,Sugandh Kumar,Samuel Yeroushalmi et al. Edward Hadeler et al.
Background: Despite their impressive efficacy in phase 3 trials, biologic agents for psoriasis (PsO) may lose efficacy over time. The factors associated with loss of efficacy have yet to be fully elucidated. ...
Clinton W Enos,Vanessa L Ramos,Robert R McLean et al. Clinton W Enos et al.
Background: Among psoriasis patients, the presence of metabolic comorbidities associates with poorer response to biologics. How the presence of comorbidity impacts treatment patterns with biologics is not fully understood...